Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Acquisitions (Tables)

Note 3 - Acquisitions (Tables)

9 Months Ended

Mar. 31, 2017

Notes Tables

Business Acquisition, Pro Forma Information [Table Text Block]

		Quarter Ended								Nine Months Ended
		March 31,								March 31,
		2017				2016				2017				2016
Net sales		$	144,037			$	136,850			$	407,642			$	381,550
Net income			26,062				30,585				66,308				81,498

Advanced Cell Diagnostics (ACD) [Member]

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

		Preliminary Allocation at Acquisition Date				Adjustments to Fair Value				Updated Opening Balance Sheet Allocation at March 31, 2017
Current assets, net of cash		$	25,196							$	25,196
Equipment			2,757								2,757
Other long-term assets			3,812								3,812
Intangible assets:
Developed technology			107,000								107,000
Trade name			17,000								17,000
Customer relationships			77,000								77,000
Non-compete agreement			200								200
Goodwill			133,780				4,677				138,457
Total assets acquired			366,745								371,422
Liabilities			3,591								3,591
Deferred income taxes, net			78,761				(7,027	)			71,734
Net assets acquired		$	284,393							$	296,097

Cash paid, net of cash acquired		$	246,193				734			$	246,927
Consideration payable			-				10,970				10,970
Fair value contingent consideration			38,200								38,200
Net assets acquired		$	284,393							$	296,097

Space [Member]

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

		Space
Current assets, net of cash		$	2,127
Equipment			159
Intangible assets:
Customer relationships			6,769
Goodwill			3,100
Total assets acquired			12,155
Liabilities			1,444
Deferred income taxes, net			1,708
Net assets acquired		$	9,003

Cash paid, net of cash acquired		$	6,747
Consideration payable			2,256